文章：

循环生物标志物与胸膜间皮瘤靶向治疗

Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma

原文发布日期：1 December 2025

DOI: 10.3390/cancers17233863

类型: Article

开放获取: 是

英文摘要：

Pleural mesothelioma (PM) is a rare and aggressive cancer. Standard of care for unresectable disease consists of chemotherapy, vascular endothelial growth factor inhibition, immunotherapy, or combinations thereof. Despite recent therapeutic advances, validated diagnostic and prognostic biomarkers are lacking, and no targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) to date. Given the growing body of research investigating molecular alterations in PM, this review summarizes emerging diagnostic and prognostic biomarkers, discusses potentially targetable molecular alterations, and examines ongoing trials directed at targeting specific molecular mechanisms in this disease.

摘要翻译： 

胸膜间皮瘤（PM）是一种罕见且侵袭性强的癌症。对于不可切除病例，标准治疗方案包括化疗、血管内皮生长因子抑制剂、免疫疗法或其组合。尽管近年来治疗手段有所进展，但仍缺乏经过验证的诊断和预后生物标志物，且迄今为止美国食品药品监督管理局（FDA）尚未批准任何靶向疗法。鉴于针对PM分子改变的研究日益增多，本综述总结了新兴的诊断与预后生物标志物，探讨了潜在的可靶向分子改变，并审视了当前针对该疾病特定分子机制开展的临床试验。

原文链接：

Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma